Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Inhaled PLGA particles of prostaglandin E₁ ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency.

Gupta V, Gupta N, Shaik IH, Mehvar R, Nozik-Grayck E, McMurtry IF, Oka M, Komatsu M, Ahsan F.

Mol Pharm. 2013 May 6;10(5):1655-67. doi: 10.1021/mp300426u. Epub 2013 Mar 26.

2.

PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl-β-cyclodextrin (PGE1-HPβCD) complex for the treatment of pulmonary arterial hypertension (PAH).

Gupta V, Davis M, Hope-Weeks LJ, Ahsan F.

Pharm Res. 2011 Jul;28(7):1733-49. doi: 10.1007/s11095-011-0409-6. Epub 2011 Apr 6.

PMID:
21626061
3.

Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension.

Gupta V, Rawat A, Ahsan F.

J Pharm Sci. 2010 Apr;99(4):1774-89. doi: 10.1002/jps.21946.

PMID:
19894275
4.

[Effects of prostaglandin E1 (PGE1) on pulmonary hypertension and lung vascular remodeling in a rat monocrotaline model of human pulmonary hypertension].

Ono S, Tanita T, Hoshikawa Y, Song C, Maeda S, Tabata T, Noda M, Ueda S, Ashino Y, Fujimura S.

Nihon Kyobu Shikkan Gakkai Zasshi. 1995 Aug;33(8):862-7. Japanese.

PMID:
7474567
5.

Influence of PEI as a core modifying agent on PLGA microspheres of PGE₁, a pulmonary selective vasodilator.

Gupta V, Ahsan F.

Int J Pharm. 2011 Jul 15;413(1-2):51-62. doi: 10.1016/j.ijpharm.2011.04.017. Epub 2011 Apr 16.

6.

Low-molecular-weight heparin (LMWH)-loaded large porous PEG-PLGA particles for the treatment of asthma.

Patel B, Gupta N, Ahsan F.

J Aerosol Med Pulm Drug Deliv. 2014 Feb;27(1):12-20. doi: 10.1089/jamp.2013.1073. Epub 2013 Nov 28.

7.
8.

Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes.

Koushik K, Dhanda DS, Cheruvu NP, Kompella UB.

Pharm Res. 2004 Jul;21(7):1119-26.

PMID:
15290850
9.

Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.

Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, Weissmann N, Schudt C, Ermert L, Seeger W, Grimminger F.

Circ Res. 2004 Apr 30;94(8):1101-8. Epub 2004 Mar 18.

10.

Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats.

Tofovic SP, Salah EM, Mady HH, Jackson EK, Melhem MF.

J Cardiovasc Pharmacol. 2005 Oct;46(4):430-7.

PMID:
16160593
11.

Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats.

Dahal BK, Kosanovic D, Kaulen C, Cornitescu T, Savai R, Hoffmann J, Reiss I, Ghofrani HA, Weissmann N, Kuebler WM, Seeger W, Grimminger F, Schermuly RT.

Respir Res. 2011 May 2;12:60. doi: 10.1186/1465-9921-12-60.

12.
13.

Inhaled nitric oxide versus intravenous vasodilators in severe pulmonary hypertension after cardiac surgery.

Schmid ER, Bürki C, Engel MH, Schmidlin D, Tornic M, Seifert B.

Anesth Analg. 1999 Nov;89(5):1108-15.

PMID:
10553820
14.

Nitric oxide versus prostaglandin E1 for reduction of pulmonary hypertension in heart transplant candidates.

Radovancevic B, Vrtovec B, Thomas CD, Croitoru M, Myers TJ, Radovancevic R, Khan T, Massin EK, Frazier OH.

J Heart Lung Transplant. 2005 Jun;24(6):690-5.

PMID:
15949728
15.

Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension.

Schermuly RT, Yilmaz H, Ghofrani HA, Woyda K, Pullamsetti S, Schulz A, Gessler T, Dumitrascu R, Weissmann N, Grimminger F, Seeger W.

Am J Respir Crit Care Med. 2005 Aug 1;172(3):358-63. Epub 2005 May 5.

PMID:
15879421
16.

Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.

Li XL, Guan RJ, Li JJ.

J Cardiovasc Pharmacol. 2012 Aug;60(2):219-26. doi: 10.1097/FJC.0b013e31825cce63.

PMID:
22592772
17.

Aerosolizable modified-release particles of montelukast improve retention and availability of the drug in the lungs.

Patel B, Rashid J, Ahsan F.

Eur J Pharm Sci. 2017 Jan 1;96:560-570. doi: 10.1016/j.ejps.2016.10.027. Epub 2016 Oct 27.

PMID:
27989858
19.

Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension.

Walmrath D, Schermuly R, Pilch J, Grimminger F, Seeger W.

Eur Respir J. 1997 May;10(5):1084-92.

20.

Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.

Schäfer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H, Kast R, Klein M.

Cardiovasc Res. 2009 Apr 1;82(1):30-9. doi: 10.1093/cvr/cvp002. Epub 2009 Jan 8.

PMID:
19131365

Supplemental Content

Support Center